Rare cancer-specific mutations in PIK3CA show gain of function
- 27 March 2007
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (13) , 5569-5574
- https://doi.org/10.1073/pnas.0701005104
Abstract
Fifteen rare cancer-derived mutants of PIK3CA , the gene coding for the catalytic subunit p110α of phosphatidylinositol 3-kinase (PI3K), were examined for their biological and biochemical properties. Fourteen of these mutants show a gain of function: they induce rapamycin-sensitive oncogenic transformation of chicken embryo fibroblasts, constitutively activate Akt and TOR-mediated signaling, and show enhanced lipid kinase activity. Mapping of these mutants on a partial structural model of p110α suggests three groups of mutants, defined by their location in distinct functional domains of the protein. We hypothesize that each of these three groups induces a gain of PI3K function by a different molecular mechanism. Mutants in the C2 domain increase the positive surface charge of this domain and therefore may enhance the recruitment of p110α to cellular membranes. Mutants in the helical domain map to a contiguous surface of the protein and may affect the interaction with other protein(s). Mutants in the kinase domain are located near the hinge of the activation loop. They may alter the position and mobility of the activation loop. Arbitrarily introduced mutations that have no detectable phenotype map either to the interior of the protein or are positioned on a surface region that lies opposite to the exposed surfaces containing gain-of-function mutants. Engineered mutants that exchange acidic or neutral residues for basic residues on the critical surfaces show a gain of function.Keywords
This publication has 31 references indexed in Scilit:
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Human Tumor Mutants in PI3K p110α SubunitCell Cycle, 2006
- Mutation of the PIK3CA oncogene in human cancersBritish Journal of Cancer, 2006
- The prevalence of PIK3CA mutations in gastric and colon cancerEuropean Journal Of Cancer, 2005
- Frequent Mutation of the PIK3CA Gene in Ovarian and Breast CancersClinical Cancer Research, 2005
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- Mutated PI 3-Kinases: Cancer Targets on a Silver PlatterCell Cycle, 2005
- Oncogenic Mutations of PIK3CA in Human CancersCell Cycle, 2004